Non-replication study of a genome-wide association study for hypertension and blood pressure in African Americans by Srividya Kidambi et al.
RESEARCH ARTICLE Open Access
Non-replication study of a genome-wide
association study for hypertension and blood
pressure in African Americans
Srividya Kidambi1,2*, Soumitra Ghosh3, Jane M Kotchen4, Clarence E Grim1, Shanthi Krishnaswami1,
Mary L Kaldunski5, Allen W Cowley Jr5, Shailendra B Patel1,2* and Theodore A Kotchen1
Abstract
Background: A recent genome wide association study in 1017 African Americans identified several single
nucleotide polymorphisms that reached genome-wide significance for systolic blood pressure. We attempted to
replicate these findings in an independent sample of 2474 unrelated African Americans in the Milwaukee
metropolitan area; 53% were women and 47% were hypertensives.
Methods: We evaluated sixteen top associated SNPs from the above genome wide association study for
hypertension as a binary trait or blood pressure as a continuous trait. In addition, we evaluated eight single
nucleotide polymorphisms located in two genes (STK-39 and CDH-13) found to be associated with systolic and
diastolic blood pressures by other genome wide association studies in European and Amish populations. TaqMan
MGB-based chemistry with fluorescent probes was used for genotyping. We had an adequate sample size (80%
power) to detect an effect size of 1.2-2.0 for all the single nucleotide polymorphisms for hypertension as a binary
trait, and 1% variance in blood pressure as a continuous trait. Quantitative trait analyses were performed both by
excluding and also by including subjects on anti-hypertensive therapy (after adjustments were made for anti-
hypertensive medications).
Results: For all 24 SNPs, no statistically significant differences were noted in the minor allele frequencies between
cases and controls. One SNP (rs2146204) showed borderline association (p = 0.006) with hypertension status using
recessive model and systolic blood pressure (p = 0.02), but was not significant after adjusting for multiple
comparisons. In quantitative trait analyses, among normotensives only, rs12748299 was associated with SBP (p =
0.002). In addition, several nominally significant associations were noted with SBP and DBP among normotensives
but none were statistically significant.
Conclusions: This study highlights the importance of replication to confirm the validity of genome wide
association study results.
Background
Hypertension is a major contributor to the global dis-
ease burden with world-wide prevalence estimated to be
~ 26%, totaling ~ 1 billion people [1,2]. Currently, in
the U.S., approximately 73 million Americans have
hypertension, and the prevalence is particularly high in
African Americans. Based on recent results of the
National Health and Nutrition Examination Survey
(NHANES), the age-adjusted hypertension prevalence is
39.1% in non-Hispanic blacks and 28.5% in non-Hispa-
nic Whites [3]. Adoption, twin, and family studies docu-
ment a significant heritable component to blood
pressure levels and hypertension [4-6] and indicate that
the heritability of blood pressure is in the range of 15-
35% [7,8]. Hypertension before the age of 55 years
occurs 3.8 times more frequently among persons with a
positive family history of hypertension [9].* Correspondence: skidambi@mcw.edu; sbpatel@mcw.edu1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
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Genome-wide association studies (GWAS) are one
strategy that is being exploited to identify the genetic
contributions to hypertension. This strategy has been
facilitated by the unraveling of the human genome, the
HapMap project, and the availability of dense computer
chips for genetic sequencing. In contrast to candidate
gene approaches, GWAS offers the potential to identify
novel mechanisms in the pathophysiology of hyperten-
sion. The first large GWAS for hypertension, performed
by the Wellcome Trust Case Control Consortium
(WTCCC) among British subjects (with 2000 cases and
3000 controls) in the [10], revealed no single nucleotide
polymorphisms (SNPs) crossing the experimental
threshold of statistical significance established at p < 10-
7. Subsequently, several additional GWAS have been
published, including 2 large-scale meta-analyses, demon-
strating sporadic and inconsistent associations of SNPs
with either blood pressure or hypertension [11-17].
Notably, these studies have been carried out in predomi-
nantly European and Amish populations.
In the first ever GWAS in African Americans (all
subjects were residents of the Washington DC area),
Adeyemo et al identified several SNPs reaching gen-
ome-wide significance for systolic blood pressure in or
near genes: PMS1, SLC24A4, YWHA7, IPO7, and
CACANA1H [18]. Two of these genes, SLC24A4 (a
sodium/potassium/calcium exchanger) and CACNA1H
(a voltage-dependent calcium channel), are potential
candidate genes for blood pressure regulation and the
latter is also a drug target for a class of calcium chan-
nel blockers. Some of the significant SNPs were repli-
cated in a sample of West Africans [18]. Independent
confirmation is necessary to validate these findings.
Therefore, we investigated the association of SNPs
identified by Adeyemo et al in an independent popula-
tion of African American subjects from the mid-wes-
tern United States. In addition, in these African
American subjects, we also sought to replicate SNP
variants recently identified by GWAS in European and
Amish populations, and further confirmed in the study
by Adeyemo et al [11,14,18].
Results
A total of 2474 eligible subjects were genotyped of
whom 53% (n = 1311) were women. Fifty-three percent
(n = 1299) of the subjects were normotensives, and 47%
(n = 1175) were hypertensives (Table 1). Of the hyper-
tensives, 50% were on antihypertensive drug therapy.
Hypertensives were older, had higher BMI, waist cir-
cumference, serum glucose, and cholesterol (p < 0.001)
compared to normotensives. There were no significant
differences in the gender composition or serum creati-
nine concentration.
Hardy-Weinberg Equilibrium
Genotype distributions were in Hardy-Weinberg equili-
brium for all the SNPs except two (rs12757682 and
rs1867226) when all the subjects were considered
together as well as when normotensives were analyzed
separately. Among hypertensives, in addition to
rs12757682 and rs1867226, rs2146204 was also not in
Hardy-Weinberg equilibrium.
Case-control association analyses
Case-control association analyses were done separately
for each SNP with hypertensives as cases and normoten-
sives as controls using PLINK association analyses. We
did not observe any statistically significant difference in
the allele frequency or in the genotype distribution of
the 24 SNPs between cases and controls (Additional file
1: Table S1). Genetic association analyses utilizing domi-
nant and additive models did not reveal any significant
associations between SNPs that were tested and hyper-
tension status (Table 2- only additive model results are
shown). One SNP (rs2146204) showed borderline asso-
ciation when recessive model was considered with a p-









Normotensives and all Hypertensives
Age (years) 45 ± 7 45 ± 7 43 ± 7 < 0.0001
Female (%) 54 44 52 0.36
SBP (mmHg) 145 ± 20 149 ± 18 118 ± 10
DBP (mmHg) 94 ± 12 98 ± 10 76 ± 8
BMI (kg/m2) 29 ± 6 28 ± 6 27 ± 5 < 0.0001
Waist circumference (cm) 93 ± 13 90 ± 12 87 ± 11 < 0.0001
Serum glucose (mg/dL) 88 ± 17 87 ± 15 85 ± 15 < 0.0001
Serum creatinine (mg/dL) 0.90 ± 0.19 0.90 ± 0.19 0.9 ± 0.18 0.335
Serum cholesterol (mg/dL) 192 ± 43 191 ± 46 184 ± 38 < 0.0001
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value of 0.006, but was not significant when adjusted for
multiple comparisons and for age, gender, BMI and
creatinine.
Quantitative trait analyses
Quantitative trait associations were carried out using
PLINK between these SNPs and systolic and diastolic
blood pressure on subjects both with and without inclu-
sion of treated hypertensive subjects (Additional file 1:
Table S2). Blood pressures of treated hypertensives were
adjusted for the effect of antihypertensive drug treatment
before conducting the analyses. While this increased the
sample size, the results were similar with both inclusion
and exclusion of treated hypertensive subjects. Neither
systolic nor diastolic blood pressures were significantly dif-
ferent among different genotypes of these 24 SNPs after
statistical adjustment for multiple comparisons. However,
without this statistical adjustment one SNP (rs2146204)
that was previously associated with diastolic blood pres-
sure in the report of Adeyemo et al, showed association
with systolic blood pressure (p = 0.02).
In additional quantitative trait analyses, we evaluated
normotensives and hypertensives separately (Additional
file 1: Table S3). In normotensives only, SNP
rs12748299 was associated with systolic blood pressure
(p = 0.002). While this was statistically significant after
adjustment for multiple comparisons, it was no longer
significant after adjustment for age, sex, BMI, serum
creatinine. Moreover, the association noted was with
lower systolic blood pressure rather than previously
associated hypertension status [18]. In addition, SNPs
rs12757682 and rs17177428 showed borderline associa-
tion with systolic and diastolic blood pressures (p =
0.04) respectively, but these were not significant after
adjustment for multiple comparisons.
Quantitative trait analyses that included only hyper-
tensive subjects (untreated and treated) showed no sig-
nificant associations of blood pressure with any of the
24 SNPs after adjustment for multiple comparisons.
However, the following several borderline associations
were observed without statistical adjustment for multiple
comparisons (Additional file 1: Table S3): a) SNP
rs1550576 was associated with systolic blood pressure (p
= 0.04); b) SNP rs17365948 was associated with systolic
and diastolic blood pressure (p = 0.004 and 0.02 respec-
tively); c) SNP rs7200009 is associated with systolic and
diastolic blood pressure (p = 0.04); d) SNP rs17177428
was associated with systolic blood pressure (p = 0.04).
The number of untreated hypertensive subjects was
insufficient to permit quantitative trait analyses in this
group of subjects.
Regression analyses
Multiple linear regression analysis did not show a statis-
tically significant impact of any of the alleles or geno-
types on systolic and diastolic blood pressure in all
subjects category (including treated subjects with
stepped-up blood pressure), in all untreated subjects
(normotensives plus untreated hypertensives), in normo-
tensives alone or in hypertensives alone (Table 3). Inde-
pendent variables included in the model were gender,
age, body mass index, and serum creatinine. Multiple
logistic regression analysis was also conducted with the
same independent variables as linear regression with
hypertension as a dependent binary trait. No significant
impact of either genotypes or alleles of all 24 SNPs was
noticed on the hypertension status.
Discussion
In this sample of African Americans, none of the SNPs
evaluated were convincingly associated with hyperten-
sion as a binary trait or with blood pressure level as a
quantitative trait. Thus, we were unable to confirm pre-
viously reported associations between PMS1, SLC24A4,
YWHA7, IPO7, and CACANA1H with systolic and
Table 2 Results of Case-control Genetic Association
Analyses using Additive Model
SNP ID Gene Symbol Minor allele MAF p-value
rs9791170 P4HA2 T 0.431 0.86
rs12757682 (AC096631.2) C 0.136 0.97
rs991316 ADH7 T 0.444 0.52
rs12748299 (AC096631.2) G 0.124 0.93
rs1550576 ALDH1A2 T 0.224 0.44
rs7902529 (AL354747.12) A 0.146 0.16
rs2146204* (RP11-375 F2.1) C 0.075 0.71
rs11160059 SLC24A4 T 0.067 0.16
rs17365948* YWHAZ T 0.012 0.43
rs5743185 PMS1 A 0.352 0.61
rs12279202* IPO7 T 0.013 0.31
rs3751664* CACNA1H T 0.015 0.34
rs8039294 SV2B G 0.451 0.44
rs10135446 NRXN3 T 0.145 0.21
rs9590141 ABCC4 A 0.107 0.76
rs1867226 PRC1 C 0.427 0.47
rs2063958* STK 39 G 0.065 0.93
rs2390639 STK 39 G 0.337 0.24
rs11890527 STK 39 C 0.388 0.42
rs2203703 STK 39 C 0.415 0.36
rs11860907 CDH 13 C 0.471 0.43
rs7200009 CDH 13 T 0.098 0.74
rs16960421 CDH 13 T 0.164 0.94
rs17177428* CDH 13 A 0.017 0.88
*p-values were obtained using modeling with Fishers exact test for dominant/
recessive tests of association when the frequency of observations was < 5 per
group
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diastolic blood pressure. However, among normotensives
only, one SNP (rs12748299) showed a significant asso-
ciation with systolic blood pressure even after adjusting
for multiple comparisons, but was no longer significant
after adjustment for age, sex, BMI and serum creatinine.
This SNP was previously marginally associated with
hypertension as a binary trait in the study by Adeyemo
et al, but had not reached genome-wide significance in
their study either. It is located on chromosome 1 in the
intergenic region and its biological plausibility is
unknown at this time.
We observed several suggestive, but not significant
associations. SNP rs2146204, located on chromosome 1
in the intergenic region, was associated with systolic
blood pressure in all subjects (treated and untreated).
Similarly, rs12757682 which is also located on chromo-
some 1 in the intergenic region, showed borderline asso-
ciation with systolic blood pressure among
normotensives. Among hypertensives, borderline asso-
ciations (p > 0.002) were noted between rs1550576 (in
the intergenic region near the gene aldehyde dehydro-
genase 1 family, member A2, ALDH1A2) and systolic
blood pressure, and rs17365948 (in the intronic region
of the gene tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide,
YWHAZ) and systolic and diastolic blood pressure. The
biological plausibility of these associations is currently
unknown (Additional file 1: Table S4).
Similarly, Ehret et al attempted to replicate six top-
associated SNPs (rs2820037 (1q43), rs6997709 (8q24),
rs7961152 (12p12), rs11110912 (12q23), rs1937506
(13q21) and rs2398162 (15q26)) from WTCCC in the
Family Blood Pressure Program (FBPP) cohort [10,19].
DNA was genotyped on 11,433 participants (39% Afri-
can Americans, 39% European Americans, 21% Hispanic
Americans) and the results showed that only one of
these six SNPs (rs1937506 on 13q21) was negatively
associated with systolic and diastolic blood pressure
among European Americans. The same SNP showed a
significant but opposite effect with systolic blood pres-
sure in Hispanic Americans and was not associated in
African Americans [19]. No replication could be shown
for hypertension status. The associations that were clo-
sest to being suggestive could not be replicated, even in
Table 3 Results of Logistic and Linear Regression Analyses using minor allele as standard
SNP ID HTN
ß ± SE (p-value)
Untreated Subjects
ß ± SE (p-value)
SBP DBP
rs9791170 -0.052 ± 0.061 (0.39) 0.000 ± 0.005 (0.66) 0.000 ± 0.005 (0.96)
rs12757682 -0.068 ± 0.088 (0.44) 0.008 ± 0.007 (0.23) 0.008 ± 0.007 (0.82)
rs991316 -0.005 ± 0.061 (0.94) 0.000 ± 0.005 (0.44) 0.000 ± 0.005 (0.89)
rs12748299 -0.041 ± 0.091 (0.65) 0.007 ± 0.007 (0.33) 0.001 ± 0.007 (0.90)
rs1550576 0.037 ± 0.072 (0.60) 0.005 ± 0.006 (0.33) 0.011 ± 0.006 (0.06)
rs7902529 -0.087 ± 0.086 (0.31) 0.001 ± 0.006 (0.88) 0.004 ± 0.007 (0.54)
rs2146204* -0.012 ± 0.117 (0.92) 0.000 ± 0.008 (0.81) 0.000 ± 0.009 (0.84)
rs11160059 0.140 ± 0.119 (0.24) 0.000 ± 0.009 (0.97) -0.010 ± 0.010 (0.53)
rs17365948* 0.149 ± 0.281 (0.60) 0.000 ± 0.023 (0.85) -0.020 ± 0.025 (0.53)
rs5743185 -0.065 ± 0.063 (0.30) 0.000 ± 0.005 (0.72) 0.000 ± 0.005 (0.55)
rs12279202* -0.209 ± 0.270 (0.44) -0.020 ± 0.021(0.35) -0.010 ± 0.022 (0.69)
rs3751664* -0.295 ± 0.253 (0.24) -0.030 ± 0.020 (0.13) -0.020 ± 0.021 (0.24)
rs8039294 0.029 ± 0.060 (0.63) 0.000 ± 0.005 (0.72) 0.001 ± 0.005 (0.81)
rs10135446 -0.123 ± 0.086 (0.15) -0.010 ± 0.006 (0.04) -0.010 ± 0.007 (0.16)
rs9590141 0.014 ± 0.097 (0.88) 0.003 ± 0.007 (0.66) 0.000 ± 0.008 (0.66)
rs1867226 -0.057 ± 0.061 (0.35) 0.005 ± 0.005 (0.27) 0.004 ± 0.005 (0.47)
rs2063958* -0.022 ± 0.121(0.86) -0.01 ± 0.009 (0.16) -0.010 ± 0.010 (0.18)
rs2390639 -0.072 ± 0.064 (0.26) -0.010 ± 0.005 (0.10) -0.010 ± 0.005 (0.17)
rs11890527 -0.060 ± 0.062 (0.34) 0.000 ± 0.005 (0.32) 0.000 ± 0.005 (0.47)
rs2203703 -0.075 ± 0.061 (0.22) 0.000 ± 0.005 (0.36) 0.000 ± 0.005 (0.44)
rs11860907 -0.042 ± 0.061(0.22) 0.000 ± 0.005 (0.76) 0.000 ± 0.005 (0.75)
rs7200009 0.051 ± 0.103 (0.60) 0.003 ± 0.008 (0.73) 0.000 ± 0.009 (0.98)
rs16960421 -0.033 ± 0.082 (0.69) 0.003 ± 0.006 (0.60) 0.002 ± 0.007 (0.73)
rs17177428* 0.006 ± 0.234 (0.98) 0.020 ± 0.018 (0.26) -0.010 ± 0.019 (0.53)
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a well characterized sample such as the FBPP suggesting
the difficulty in replicating the findings of GWAS [19].
The most significant criticism of the WTCCC was the
use of young controls that could potentially become
cases at a later age.
Inconsistent results among several small-scale GWAS
[11-14,20] suggested that hypertension is polygenic dis-
ease with multiple low frequency genes acting in har-
mony to result in elevated blood pressure. To overcome
some of these limiting factors, a large meta-analysis of
CHARGE and BPgen Consortium results was conducted
recently and several novel loci have been identified for
blood pressure. Although these associations have not
been replicated in independent populations, these results
may be more robust than previous GWAS as the meta-
analysis involved more than 60,000 subjects [15,16]. We
did not choose to replicate these associations as these
studies involved subjects primarily from European and
Asian Indian ancestry.
On a similar note, a large GWAS for blood pressure
among African Americans, the Candidate Gene Associa-
tion Resource (CARe) Study, has recently been pub-
lished. In a meta-analysis across five community-based
cohorts, two novel loci were identified that reached sta-
tistical significance: rs2258119 on chromosome 21 with
systolic blood pressure and rs10474346 on chromosome
5 with diastolic blood pressure [21]. However, neither of
these associations were replicated in independent Afri-
can American samples, again highlighting the difficulty
in extending the findings of GWAS to independent
populations. In addition, this study did not identify any
of the loci identified by Adeyemo et al.
Even though the evidence for a genetic contribution
remains robust, the effect of environment may be a
major modifier, and this may be the reason for inconsis-
tent data. Many common everyday activities can pro-
foundly affect blood pressure, such as salt intake,
exercise, stress, etc., and many of these are not quanti-
tated in population-based studies. To minimize environ-
mental and genetic variability, Wang et al carried out a
GWAS of systolic and diastolic blood pressure in Amish
subjects [11]. Strong association signals with several
common variants in a serine/threonine kinase gene
(STK39) were found and they confirmed these associa-
tions in an independent Amish and 4 non-Amish Cau-
casian samples [11]. Adeyemo et al found that several
SNPs in this gene were associated with the blood pres-
sure (9/136 for systolic blood pressure and 33/136 for
diastolic blood pressure) in African Americans. Variants
in STK39 may influence blood pressure by increasing
STK39 expression and consequently altering renal
sodium excretion [11]. We were unable to confirm the
associations of 2 top-associated SNPs in this gene for
systolic and diastolic blood pressure in our cohort
despite having adequate power. These associations were
not tested in CARe study by Fox et al.
Another novel locus contributing to blood pressure
was identified by Org et al in a GWAS of a German
population and is known as Cadherin 13-Heart
(CDH13) [14]. CDH13 is a calcium-dependent cell adhe-
sion glycoprotein and may mediate interaction between
cells in heart. Several SNPs in this locus were also
found to be associated with systolic and diastolic blood
pressures among African Americans by Adeyemo et al.
We tested the association of 4 of these SNPs with
hypertension as a binary trait and blood pressure as a
quantitative trait in our sample. We confirmed a border-
line association (insignificant when considered with
multiple tests) of rs17177428 and rs7200009 with blood
pressure as quantitative trait among hypertensive and
normotensive subjects. Again, this association was not
tested in CARe study by Fox et al.
As evidenced by these studies, identification of genetic
contributors to hypertension remains challenging for
several reasons. Population heterogeneity, environmental
effects, and sample size all contribute to these failures.
Our study is also subject to these criticisms. In addition,
as already eluded to, inheritance of blood pressure is
polygenetic where in a single gene or combination of
genes act in concert with above mentioned environmen-
tal exposures to contribute only a modest effect on
blood pressure. Indeed, genetic variants identified by
GWAS contribute to only a small effect on blood pres-
sure (1-2 mmHg). Although this may have a population-
based impact, this effect may not be discernible among
individuals. Moreover, the difficulty of obtaining a stan-
dardized blood pressure phenotype cannot be over
emphasized.
We also acknowledge the limitations of using com-
mercially available tag SNPs. While it is possible to
identify genetic variation with tag SNPs without geno-
typing every SNP in the chromosomal region and are
widely used in genome-wide association studies, it may
make replication of target SNPs difficult due to differ-
ences in linkage disequilibrium between two samples.
For this reason, many studies have now adopted the
technique of “local replication” in which SNPs sur-
rounding tag SNP are also targeted, especially for SNPs
that are not directly replicated from previous studies
[22].
Apart from inherent difficulties in identifying genetic
determinants of hypertension due to the phenotype itself
as well as methods, we acknowledge that the differences
between the populations investigated by our study and
Adeyemo et. al. may account for non-replication of the
GWAS. Since African Americans as an ethnic group are
quite diverse with different origins, we recruited only
the individuals whose parents were both born in the
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United States, with English as their first language, to
achieve some uniformity in ethnicity. However, this may
not have been sufficiently homogeneous population and
the differences in the results may reflect different popu-
lation admixture rates [23,24]. Since we do not know
the admixture rate in our population, we were unable to
adjust for that while Adeyemo et. al used genome-wide
markers to compute principal components and used
these in their models. These baseline differences in the
African American population composition is also
reflected in the allele frequencies of the various SNPs, e.
g. CACNA1H (0.015 vs 0.109), IPO7 (0.013 vs 0.123),
YWHAZ (0.012 vs 0.113), SLC24A4 (0.067 vs 0.178),
PMS1 (0.352 vs 0.148) (Additional file 1: TableS 5).
There were several strengths to our study. Cases and
controls were clearly defined with normotensives having
blood pressures in the lower third of the population dis-
tribution of blood pressure (~ 3 SD below the untreated
hypertensive means) to eliminate the bias of cases mas-
querading as controls or vice versa. Subjects with sec-
ondary hypertension were excluded including those with
renal insufficiency. In addition, the mean age of the
cases and controls are in mid-forties, which is suffi-
ciently young to capture genetically determined blood
pressure increases and old enough to capture most pri-
mary hypertensives. However, it is still possible some
mis-classification of cases and controls might have
occurred.
Conclusions
While they are relatively easy to perform, interpretation
of the results of successful association studies is neither
straightforward nor always replicable. In addition, over-
estimation of genetic effect size in initial studies due to
“winner’s curse” may cause follow-up studies to be
underpowered and so to fail [25]. Results of the current
study and others do not replicate previously identified
hypertension-related SNPs in GWAS. Non-genetic fac-
tors particularly environment, profoundly affect the
impact of genes on blood pressure and hypertension
and inherited phenotypes may potentially be a result of
mechanisms without change in underlying DNA
sequence. Consequently, in addition to focusing on
replication of GWAS findings, future studies may need
to move beyond DNA-based sequence approaches and




The study was approved by the Froedtert Memorial
Lutheran Hospital/Medical College of Wisconsin Insti-
tutional Review Board. Unrelated African Americans
subjects between the ages of 18-55 years were recruited
from a variety of community resources and health care
providers within the Milwaukee area. Subjects were
defined as African Americans based on self-identifica-
tion, birth in the continental United States, both parents
reported as being African Americans, and English as the
native language. All subjects were evaluated during a
single outpatient visit and were considered to have
hypertension if standardized outpatient measurement of
systolic blood pressure was ≥ 140 mmHg, diastolic
blood pressure was ≥ 90 mmHg and/or if they were tak-
ing antihypertensive medications. Blood pressures of
normotensives were in the lower third of the distribu-
tion of population blood pressures. Pregnant subjects,
subjects with diabetes mellitus (fasting blood glucose ≥
126 mg/dL (6.93 mmol/L) or random blood sugar > 200
mg/dL (11 mmol/L), and subjects with serum creatinine
concentrations ≥ 1.3 mg/dL (114.92 μmol/L) were
excluded.
After subjects provided informed consent, standar-
dized measurements of blood pressure and anthropo-
metric measurements including height, weight, and
waist circumference were acquired. Blood pressures
were taken by trained and certified personnel according
to the American Heart Association guidelines by the
Shared Care Method using a sphygmomanometer [27].
After being seated for at least 5 minutes, 2 readings
were obtained from each arm using an appropriate sized
arm cuff and the average of the arm with the higher
measurement was used for the visit reading. Waist cir-
cumference was taken at the narrowest point between
the umbilicus and superior iliac crest. Serum glucose
was measured with an automated glucose oxidase enzy-
matic assay. Plasma cholesterol was measured using an
enzymatic procedure.
Selection of SNPs and genotyping
SNPs associated with hypertension and blood pressure
in the genome wide association study by Adeyemo et al
among AAs were selected for the study [18]. As shown
in Additional file 1: Table S4, these include the follow-
ing: a) seven top-associated SNPs for hypertension as a
binary trait b) five top associated SNPs for systolic
blood pressure as a continuous trait and c) four top-
associated SNPs for diastolic blood pressure. In addition,
8 variants in 2 genes (STK39 and CHD13) identified in
European and Amish populations [11,14] and replicated
by Adeyemo et al [18] in African Americans were also
selected for replication in the current study. Among
these SNPs, only a few had reached genome-wide signif-
icance for systolic BP in the study by Adeyemo et. al.
There are the SNPs in or near the genes: PMS1
(rs5743185), SLC24A4 (rs11160059), YWHA7
(rs17365948), IPO7 (rs12279202), and CACANA1H
(rs3751664). In addition, STK39 and CHD 13 gene
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variants reached genome wide significance in non-Afri-
can American populations.
DNA was extracted manually from peripheral white
blood cell pellets using reagents from Qiagen (Qiagen
Inc. Valencia, CA, USA) and precipitated using isopro-
panol [28]. TaqMan MGB-based chemistry (Applied
Biosystems, Foster City, CA, USA) with fluorescent
probes was used for all genotyping. Genotypes were
called using the manufacturer’s software and all data
were inspected manually. In our laboratory, this method
has ~99% concordance between duplicate samples, and
produces a genotype for 97.4% of all samples attempted
with 95% validity. Approximately 1.8% of the samples
were deemed indeterminate or failures.
Statistical methods
Continuous variables were reported as means ± standard
deviation (SD). Differences in the distributions of all
selected phenotypes between hypertensive and normo-
tensive subjects were determined either by Student’s t-
test or by Wilcoxon rank sum test, depending upon the
distribution of variables. Both SAS software version 9.1
(SAS Institute, CARY, NC) and PLINK [29] were used
for analyses. PLINK was used to perform genetic asso-
ciation analyses considering log-additive, dominant, and
recessive models for both quantitative and qualitative
traits. Deviations of the observed allele frequencies from
those expected under Hardy-Weinberg equilibrium were
tested by the c2 -test. In case-control analyses, odds
ratios for hypertension were calculated using the major
allele as reference. When analyzing systolic and diastolic
blood pressures as continuous traits, to account for the
treatment effect amongst those on anti-hypertensive
medications, we used stepped addition of blood pres-
sures to treated subjects based on number of drugs a
subject was taking. As previously described by others
[30], stepped increments of 8/4 mmHg, 14/10 mmHg,
and 20/16 mmHg were added to measured systolic and
diastolic blood pressures of treated subjects taking 1, 2,
and ≥ 3 drug classes, respectively. These stepped incre-
ments were chosen to achieve an average increase of 10/
5 mmHg in treated subjects. Analyses for blood pressure
as a continuous trait were also performed excluding
subjects on antihypertensive medications.
P-values < 0.002 were deemed as significant after
adjustment for multiple tests. One-way ANOVA was
conducted to assess if there was a difference in the
blood pressure among all 3 genotypes for each SNP.
Multiple linear regression analyses were carried out with
systolic and diastolic blood pressures as continuous
dependent variables and multiple logistic regression with
hypertension as categorical dependent variable. SNPs
were represented as categorical variables either as minor
allele or as homozygous genotype of minor allele in
both logistic regression and linear regression analyses.
Other independent variables included gender, age, BMI,
and creatinine in the same model.
Power calculations were performed using the pro-
gram Quanto v1.1 (James Gauderman, University of
Southern California, USA) [31]. Power for unmatched
case-control (case-control ratio = 1:1) studies was esti-
mated using actual allelic frequencies of tested genetic
markers ranging from 0.01 to 0.5, a log-additive model,
a disease prevalence of 33% and a type 1 error rate of
0.002. Sample sizes were estimated for genetic effect
sizes (odds ratios) of 1.3 to 2.3 with the log-additive
model. Due to different minor allele frequencies
(MAFs) for different SNPs, we listed the minimal effect
size (odds ratio) that could be detected with the avail-
able sample size for the qualitative trait analyses
(Additional file 1: Table S6). To estimate power in a
continuous trait analysis, systolic and diastolic blood
pressures were used as a continuous outcome for inde-
pendent subjects, with an additive model and a type 1
error rate of 0.002 and an effect size of 1% variance. A
sample size of 781 was needed to detect a difference of
1 mmHg of blood pressure.
Additional material
Additional file 1: Table S1. Genotype distribution of all 24 SNPs in
cases and controls. Table S2 - Quantitative trait analyses. Table S3-
Quantitative trait analyses in normotensive and hypertensive subjects.
Table S4 - List of single-nucleotide polymorphisms (SNPs) genotyped.
Table S5- Results of current study in comparison to study by Adeyemo
et. al. Table S6 - Power calculation of effect size detectable based on
minor allele frequency in case-control analyses.
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